• By ICR Secretariat
  • Posted Tuesday, June 21, 2022

FDA advisers offer unanimous support to second Bluebird gene therapy

https://www.biopharmadive.com/news/bluebird-bio-fda-meeting-gene-therapy-beta-thalassemia/625298/

For the second time in two days, advisers to the Food and Drug Administration gave their unanimous support to an experimental gene therapy for a rare inherited disease, agreeing its benefits outweigh its risks.